Virus Allianz NRW Standort Bonn Study

Virus Allianz NRW Standort Bonn Study - VIRABO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031836

Enrollment

1696

Registered

2023-08-09

Start date

2022-06-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Participants who have already been enrolled in the DRKS00021306 and/or DRKS00023113 studies will be invited to participate in the collection of biological samples (blood, saliva, and throat s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consenting residents of Heinsberg or Rheinbach and prior participation in at least one of the two studies DRKS00021306 or DRKS00023113 or random selection by the local government based on resident data.

Exclusion criteria

Exclusion criteria: (i) Refusal of informed consent. (ii) Contraindication to the selected specimen collection methods (venipuncture or capillary blood collection via fingertip or throat swab).

Design outcomes

Primary

Measure	Time frame
Prevalence of SARS/CoV-2 positive participants in the study population, defined as the number of participants with a positive laboratory result (from at least one of the media sampled in the study) divided by the total number of study participants at each survey time point.	—

Secondary

Measure	Time frame
(i) Incidence of new infections as the proportion of participants with a positive laboratory result (from at least one of the specimens collected in the study) with a previous negative SARS-CoV2 IgG/PCR result (3-month incidence). (ii) Incidence of reinfection in the population determined by the proportion of participants with a repeat positive swab result with a previous positive SARS-CoV2 IgG/PCR result. (iii) Determination of the progression of antibody titers over a defined period of time. (iv) Infection rate, defined as the number of participants with new positive laboratory findings (per study section) divided by the total number of study participants and per time period. (v) comparison of symptoms recorded in the questionnaire over time and between infection events (vi) Comparison of exposure of infected and uninfected participants to personal and behavioral factors.	—

Measure

Time frame

(i) Incidence of new infections as the proportion of participants with a positive laboratory result (from at least one of the specimens collected in the study) with a previous negative SARS-CoV2 IgG/PCR result (3-month incidence). (ii) Incidence of reinfection in the population determined by the proportion of participants with a repeat positive swab result with a previous positive SARS-CoV2 IgG/PCR result. (iii) Determination of the progression of antibody titers over a defined period of time. (iv) Infection rate, defined as the number of participants with new positive laboratory findings (per study section) divided by the total number of study participants and per time period. (v) comparison of symptoms recorded in the questionnaire over time and between infection events (vi) Comparison of exposure of infected and uninfected participants to personal and behavioral factors.

—

Countries

Germany

Contacts

Public ContactHendrik Streeck

Institut für Virologie/Universitätsklinikum Bonn

virologie@ukbonn.de+49 228 28710454

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026